（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司电解液、六氟磷酸锂、双氟、VC等产品最 新产能分别是多少？ 永太科技（002326.SZ）1月8日在投资者互动平台表示，公司目前已投产电解液产能15万吨/年，固态六 氟磷酸锂产能1.8万吨/年，液态双氟磺酰亚胺锂产能6.7万吨/年，VC产能1万吨/年。 ...

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang Province, specializing in fluorine fine chemicals [2] - The company operates multiple production bases across Zhejiang, Inner Mongolia, Fujian, and Guangdong, ensuring sufficient capacity to support future growth [2] Financial Performance - In the first three quarters of 2025, the company achieved revenue of CNY 402,835.11 million, a year-on-year increase of 20.65% [3] - The net profit attributable to shareholders was CNY 32.55 million, marking a turnaround from losses [3] Business Segments and Future Strategies Lithium Battery Materials - The company has established a vertically integrated supply chain for lithium materials, with production capacities as follows: - Solid lithium hexafluorophosphate: 18,000 tons/year - Liquid lithium bis(fluorosulfonyl)imide: 67,000 tons/year - Additives: VC at 10,000 tons/year (with an additional 5,000 tons/year in trial production) and FEC at 3,000 tons/year - Electrolyte: 150,000 tons/year [3] - Future plans include enhancing R&D and product offerings to meet customer needs in the lithium battery sector [3] Pharmaceutical Sector - The company has developed a vertical supply chain for fluorinated intermediates and APIs in cardiovascular, diabetes, CNS, and antiviral fields [3] - Future focus will be on advanced technologies to deepen development in these therapeutic areas [3] Agricultural Chemicals - The agricultural segment focuses on fluorinated herbicides, fungicides, and insecticides, leveraging vertical integration to enhance product offerings [4] - Plans include expanding production capacity and improving sustainability in agricultural solutions [4] Market Dynamics and Supply Chain Management - The company monitors the price cycle of lithium hexafluorophosphate, with production capacity currently at 18,000 tons/year, and will evaluate expansion plans based on market conditions [4] - A moderate inventory strategy for lithium carbonate is in place to mitigate financial risks while ensuring stable supply [5] Customer Relationships and Market Position - The company has established long-term partnerships with leading firms such as CATL and BYD in the lithium battery sector [8] - The agricultural and lithium materials segments have shown significant revenue growth, with agricultural revenue increasing by 39.77% and lithium materials by 112.09% year-on-year [9] Challenges and Adjustments - The pharmaceutical segment faced a revenue decline of 30.62% due to patent expirations and increased competition [9] - The company is actively adjusting production and sales strategies in response to market dynamics, particularly in the VC product line [5][7]

Group 1 - The core viewpoint of the articles highlights the robust growth in the lithium battery sector, driven by increasing demand for electric vehicles and energy storage systems, leading to a favorable pricing environment for electrolyte products [1][2]. - Yongtai Technology has a current electrolyte production capacity of 150,000 tons per year, with production gradually ramping up and sales volume increasing year-on-year [1]. - The company's lithium battery and other materials segment achieved revenue of 871 million yuan in the first half of 2025, accounting for 33.38% of total revenue, representing a year-on-year growth of 105.74% [1]. Group 2 - In the first half of 2025, China's new energy vehicle sales reached 6.968 million units, reflecting a year-on-year growth of 41.4% [2]. - The demand for energy storage is benefiting from long-term domestic orders and the postponement of U.S. tariffs, leading to a sustained increase in demand [2]. - The introduction of new technologies, such as lithium battery "injection restoration," is expected to strengthen Yongtai Technology's market position in the lithium battery materials sector [2]. Group 3 - The new lithium additive, trifluoromethyl sulfonyl lithium, can extend battery life significantly and is currently being produced in small quantities for leading lithium battery companies [3]. - If 50% of the global lithium battery electrolyte demand in 2025 requires the addition of 3-5% of this new additive, the demand could reach approximately 30,000 to 50,000 tons, with a market potential exceeding 10 billion yuan [3].

Group 1 - The core point of the article is that Yongtai Technology has successfully ramped up its production capacity for electrolyte to 150,000 tons per year, with production and sales scale increasing year-on-year [1] - The company’s downstream customers primarily consist of leading enterprises in the lithium battery sector [1] - The production capacity for liquid dual fluorosulfonyl imide lithium stands at 67,000 tons per year, with the capacity utilization rate steadily improving [1]

Core Viewpoint - Yongtai Technology has reported that its current electrolyte production capacity is 150,000 tons per year, with production gradually ramping up and sales volume increasing year-on-year. The company primarily serves leading lithium battery manufacturers [1] Group 1: Production Capacity - The company's current electrolyte production capacity stands at 150,000 tons per year [1] - The production capacity is being gradually released, indicating a positive trend in operational efficiency [1] Group 2: Sales and Clients - Sales volume is experiencing a year-on-year growth, reflecting strong demand in the market [1] - The main downstream clients are major players in the lithium battery sector [1] Group 3: Dual Fluoride Production - The company's production capacity for liquid dual-fluoro sulfonyl imide lithium is 67,000 tons per year [1] - The utilization rate of this capacity is steadily increasing, suggesting improved operational performance [1]

Core Insights - Yongtai Technology (002326.SZ) reported a revenue of 4.589 billion yuan for the year 2024, marking an 11.18% year-on-year increase, while the net profit loss narrowed by 36.26% to -443.87 million yuan, indicating progress in operational efficiency and profitability [1] - The lithium battery materials segment saw an 18.07% revenue growth, with gross margin improving from -28.31% to -5.24%, driven by technological improvements and cost reduction measures [1] - The plant protection segment experienced a significant revenue increase of 91.79%, with gross margin rising by 2.65 percentage points, attributed to successful project launches and recovering downstream demand [1] Revenue and Profitability - The pharmaceutical segment faced a 3.57% revenue decline due to increased market competition and price drops following patent expirations, with gross margin decreasing by 0.77 percentage points [2] - Despite challenges, the company managed to limit the revenue decline through stable partnerships and market expansion strategies [2] Technological Advancements - Yongtai Technology has established a dual-channel development strategy in the pharmaceutical sector, focusing on high-value and stable raw materials and formulations [3] - The company’s subsidiaries achieved significant regulatory milestones, including FDA inspections and drug registration certificates, enhancing its market expansion capabilities [3] Production and Operational Efficiency - The company is focusing on core project development and optimizing its industrial chain layout to achieve economies of scale, with a lithium project entering trial production [4] - Yongtai Technology's lithium battery electrolyte shipment volume has entered the top ten in China, reflecting improved market competitiveness [4] Market Position and Collaborations - The company has formed long-term partnerships with major firms like Merck and BASF, strengthening its market position [2] - Yongtai Technology is leveraging overseas pesticide registration resources to expand its market share in the plant protection sector [4] Research and Development - The company has established R&D centers in Zhejiang and Shanghai, with an AI-driven drug development platform enhancing its research capabilities [5] - Yongtai Technology has successfully transformed multiple research outcomes into production, optimizing processes and reducing costs [6] Intellectual Property and Innovation - The company has applied for a total of 221 invention patents, with 171 granted, emphasizing its commitment to intellectual property protection [6] - The year 2024 is characterized by significant advancements across various sectors, reinforcing the company's competitive edge through innovation and market expansion [6]